Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer

References

• Cancer Society of Finland. Cancer incidence in Finland 1996–97. Finnish Cancer Registry, Helsinki 2000, Publication No 61
   Google Scholar
• Carney D, Hansen H. Non-small-cell lung cancer - Stalemate or progress. N Engl J Med 2000; 343: 1261–2
   PubMed Web of Science ®Google Scholar
• Teppo L, Salminen E, Pukkala E. Risk of a new primary cancer among patients with lung cancer of different histo-logical types. Eur J Cancer 2001; 37: 613–9
   PubMed Web of Science ®Google Scholar
• Dickman P, Hakulinen T, Luostarinen T. Survival of cancer patients in Finland 1955–1994. Acta Oncol 1999; 37(Suppl 12)1–103
   Google Scholar
• Marcus P, Bergstralh E, Fagerström R, Williams D, Fontana R, Taylor W, et al. Lung cancer mortality in the Mayo Lung Project. Impact of extended follow-up. J Natl Cancer Inst 2000; 92: 1308–16
   PubMed Web of Science ®Google Scholar
• Fontana R, Sanderson D, Woolner L, Taylor W, Miller W, Muhm J, et al. Screening for lung cancer. A critique of the Mayo Lung Project. Cancer 1991; 67(4 Suppl)1155–64
   PubMed Web of Science ®Google Scholar
• Ginsberg R, Goldberg M, Waters P. Surgery for non-small cell lung cancer. Thoracic oncology. 2nd edn, J Roth, J Ruckdeschel, T Weisenberger. WB Saunders, Philadelphia, PA 1995; 124
   Google Scholar
• Asamura H, Nakayma H, Kondo H, Tsuchiya R, Shimasato Y, Naruke K. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy. J Thorac Cardiovasc Surg 1996; 111: 1125–34
   PubMed Web of Science ®Google Scholar
• Feld R, Rubinstein L, Weisenburger T. Sites of recurrence in resected stage I non-small cell lung cancer. A guide for future studies. J Clin Oncol 1985; 2: 1352–8
   Web of Science ®Google Scholar
• Werner-Vasik M, Scott C, Cox J, Sause W, Byhardt R, Asbell S, et al. Recursive partitioning analysis of 1999 radiation therapy oncology group (RTOG) patients with locally advanced non small cell lung cancer: identification of five groups with different survival. Int J Radiat Oncol Biol Phys 2000; 48: 1475–82
   PubMed Web of Science ®Google Scholar
• Chemotherapy in NSCLC. a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small-cell lung cancer collaborative group. BMJ 1995; 311: 899–909
   PubMedGoogle Scholar
• Mornex F, Van Houtte P, Scalliet P, Loubeyre P. Radiotherapy for non-small-cell bronchial cancers: definitions of volumes, patient selection. Recommendations of the International Association for the Study of Lung Cancer (IASLC). Cancer Radiother 1998; 2: 579–89
   PubMedGoogle Scholar
• Kadri M, Dussek J. Survival and prognosis following resection of primary non small cell bronchogenic carcinoma. Eur J Cardiothorac Surg 1991; 5: 132–6
   PubMed Web of Science ®Google Scholar
• Bradley J, Deasy J, Purdy J, Wasserman T, Graham N, Ieumwananonthachai N, et al. Gross tumor volume is an independent predictor of survival in non-small cell lung carcinoma patients treated with conformal radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48(Suppl 3)129–30
   Google Scholar
• Vesselle H, Schmidt R, Pugsley J, Li M, Kohlmyer S, Vallieres E, et al. Lung cancer proliferation correlates with F-18 Fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000; 6: 3837–44
   PubMed Web of Science ®Google Scholar
• Weng E, Tran L, Rege S, Safa A, Sadeghi A, Juillard G, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol 2000; 23: 47–52
   PubMed Web of Science ®Google Scholar
• Saunders C, Dussek J, O'Doherty M, Maisey M. Evaluation of fluorine-18-fluorodeoxyglucose whole body emision tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999; 67: 790–7
   PubMed Web of Science ®Google Scholar
• Scott W, Gobar L, Terry J, Dewan N, Sunderland J. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996; 111: 642–8
   PubMed Web of Science ®Google Scholar
• Gupta N, Graebner G, Rogers J, Bishop H. Comparitive efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1999; 229: 286–91
   PubMed Web of Science ®Google Scholar
• Dwamena B, Sonnad S, Angobaldo J, Wahl R. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta analytic comparison of PET and CT. Radiology 1999; 213: 530–6
   PubMed Web of Science ®Google Scholar
• Weder W, Schmid R, Bruchhaus H, Hillinger S, Von Schulthess C, Largiader F, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66: 886–92
   PubMed Web of Science ®Google Scholar
• Erasmus J, Patz E, McAdams H, Murray J, Herndon J, Coleman R, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. Am J Roentgenol 1997; 168: 1361–2
   PubMed Web of Science ®Google Scholar
• Bury T, Barreto A, Daenen F, Bartelelemy N, Ghaye B, Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non small cell lung cancer. Eur J Nucl Med 1998; 15: 1244–7
   Google Scholar
• Schumacher T, Brink T, Mix M, Reinhardt M, Herget G, Digel W, et al. FDG-PET imaging for the staging and follow-up of non small cell lung cancer. Eur J Nucl Med 2001; 28: 483–8
   PubMedGoogle Scholar
• McKenna R, Libshitz H, Mountain C, McMurtrey M. Roentgenographic evaluation of mediastinal nodes for preoperative assesment in lung cancer. Chest 1985; 88: 206–10
   PubMed Web of Science ®Google Scholar
• Gupta N, Graeber G, Bishop H. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<lcm), intermediate (1 to 3 cm) and large (>3 cm) lymph node lesions. Chest 2000; 117: 773–8
   PubMed Web of Science ®Google Scholar
• Liewald F, Grosse S, Storck M, Guhlmann A, Halter G, Reske S, et al. How useful is positron emission tomography for lymphnode staging in non-small cell lung cancer. Thorac Cardiovasc Surg 2000; 48: 93–6
   PubMed Web of Science ®Google Scholar
• Berlangieri S, Scott A. Metabolic staging of lung cancer. N Engl J Med 2000; 343: 290–1
   PubMed Web of Science ®Google Scholar
• Pieterman R, van Putten J, Meuzelaar J, Moovaart E, Vaalburg W, Koeter G, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343: 254–61
   PubMed Web of Science ®Google Scholar
• Digby W, Keppler J. The current status of positron emission tomography. Radiol Manage 2000; 22: 37–40
   PubMedGoogle Scholar
• Mac Manus M, Hicks R, Matthews J, Hogg A, McKenzie A, Wirth A, et al. High rate of detection of unsuspected metastases by PET in apparent stage III NSCLC: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 287–93
   PubMed Web of Science ®Google Scholar
• Mac Manus M, Hicks R, Ball D, Kalff V, Matthews J, Salminen E, et al. FDG-PET staging in radical radiotherapy candidates with non-small cell lung cancer: powerful correlation with survival and high impact on treatment. Cancer, (in press)
   Google Scholar
• Kalff V, Hicks R, MacManus M, Binns D, McKenzie A, Ware R, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001; 19: 111–8
   PubMed Web of Science ®Google Scholar
• Schmuecking M, Plichta K, Lopatta E, Przetak C, Leonhardi J, Gottschild D, et al. Image fusion of F-18 FDG PET and CT-is there a role in 3D-radiation treatment planning of non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2000; 48((Suppl) 3)130
   Google Scholar
• Vanuytsel L, Vansteenkiste J, Stroobants S, De Leyn P, De Wever W, Verbeken E, et al. The impact of 18 F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in 46. patients with non-small cell lung cancer. Radiother Oncol 2000; 55: 317–24
   PubMed Web of Science ®Google Scholar
• Vaylet F, Foehrenbach H, Guigay J, deDreuille O, Maszelin P, Grassin F, et al. Positron emission tomography in thoracic radiography. Cancer Radiother 2000, Suppl 1: 13s–16s
   Google Scholar
• Mac Manus M, Hicks R, Ball D, Cavarella F, Binns D, Hogg A, et al. Imaging with F-18 FDG PET is superior to T1–201 SPECT in the staging of non-small-cell Lung cancer for radical radiation therapy. Australasian Radiol, (in press)
   Google Scholar
• Dunagan D, Chin R, McCain T, Case L, Harkness B, Oaks T, et al. Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. Chest 2001; 119: 333–9
   PubMed Web of Science ®Google Scholar
• Young H, Baum R, Cremerius U, Henholz K, Hoekstra O, Lammertsma A, et al. Measurement of clinical and subclinical tumour response using FDG and PET: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35: 1773–82
   PubMed Web of Science ®Google Scholar
• Mac Manus M, Hicks R, Wada M, Hogg A, Matthews J, Wirth A, et al. Early F-18 FDG-PET response to radical chemoradiotherapy correlates strongly with survival in un-resectable non-small cell lung cancer. Proc Am Soc Clin Oncol 2000; 19: 483a
   Google Scholar
• Kosuda S, Ichihara K, Watanabe M, Kobayashi H, Kusano S. Decision tree sensitivity analysis for cost-effectiveness of chest FDG-PET in patients with a pulmonary tumour (NSCLC). Kaku-lgaku 1998; 38: 395–404
   Google Scholar
• Tesar R, Papatheofanis F, Valk P. Reimbursement and technology assessment for positron imaging. Clin Positron Imaging 1998; 1: 51–8
   PubMedGoogle Scholar
• Gambhir S, Hoh C, Phelphs M, Madar I, Maddahi J. Decision tree sensitivity analysis for cost effectiveness of FDG-PET in the staging and management of non-small cell lung carcinoma. J Nucl Med 1996; 37: 1428–36
   PubMed Web of Science ®Google Scholar
• Marom E, Erasmus J, Patz E. Lung cancer and positron emission tomography with fluorodeoxyglucose. Lung Cancer 2000; 28: 187–202
   PubMed Web of Science ®Google Scholar
• Van Tinteren H, Hoekstra O, Smit E, Van den Bergh A, Schreurs R, Stallaert F, et al. Randomized controlled trial to evaluate the cost effectiveness of positron emission tomography (PET) added to conventional diagnosis in non-small cell lung cancer. Proc Am Soc Clin Oncol 2000; 19: 482a
   Google Scholar
• O'Doherty M, Marsden P. Being equipped for clinical PET. Lancet 2000; 356: 1701–3
   PubMed Web of Science ®Google Scholar
• Report of the Medical Services Advisory Committee. Department of Health and Aged Care, Commonwealth of Australia, CanberraAustralia 2001, (http://www.health.gov.au/haf/msac)
   Google Scholar
• Vansteenkiste J, Stroobants S, Dupont P, De Leyn P, Verbeken E, Deneffe G, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17: 3201–6
   PubMed Web of Science ®Google Scholar
• Beyer T, Townsend D, Brun T, Kinahan P, Charron M, Roddy R, et al. A combined PETKT scanner for clinical oncology. J Nucl Med 2000; 41: 1369–79
   PubMed Web of Science ®Google Scholar